

COVID-19'DA ORGAN SPESİFİK TUTULUMLAR, KOMPLİKASYONLAR VE PROGNOSTİK FAKTÖRLER

Ahmed BİLAL GENÇ¹
Selçuk YAYLACI²

GİRİŞ

COVID-19 (SARS-CoV-2) ön planda damlacık yoluyla bulaşan bir viral enfeksiyon olarak gözükse de tüm organ sistemlerini etkileyecek düzeyde komplikasyonlara neden olmaktadır. Literatürde pulmoner, extrapulmoner (kardiyovasküler, nörolojik, hematolojik vs) bir çok komplikasyon bildirilmektedir.

Gerek yaş, cinsiyet, kronik hastalıklar gibi demografik veriler gerekse de birçok laboratuvar parametresi hastalığın prognostik faktörleri olarak kullanılmaya başlanmıştır. yaş, erkek cinsiyet, sigara içimi, eşlik eden komorbid hastalıklar, C-Reaktif protein (CRP), prokalsitonin, nötrofil yüksekliği, albumin, trombosit ve lenfosit düşüklüğü bildirilen kötü sonlanım faktörlerinden bazılarıdır.

Bu bölümde COVID-19 hastalarında oluşabilecek organ spesifik tutulumları, komplikasyonları

ve prognostik faktörleri literatür eşliğinde incelenmesi amaçlanmıştır.

COVID-19'DA organ spesifik tutulumlar ve komplikasyonlar

Pulmoner tutulum ve komplikasyonlar

SARS-CoV-2 enfeksiyonu ile ilişkili akciğer tutulumunun ciddiyeti, hafif pnömoniden (%81), şiddetli hastalıkla ilişkili hipoksiye (%14), kritik hastalıkla birlikte şok, solunum yetmezliği ve çoklu organ yetmezliğine (%5) ve ölüme (%2.3) kadar ilerleyebilir[1,2]. Bilinen akciğer hastalığı olan bireylerde COVID-19 mortalitesi de daha yüksek olduğu vurgulanmaktadır[3].

Hastanede yatan hastaların bir bölümünde akut solunum sıkıntısı sendromu (ARDS) gelişebilmektedir[4]. Toplam 663 hastanın dâhil edildiği ve total mortalitenin %31 (203 hasta) olduğu bir çalışmada, ARDS, mortal seyreden

¹ Uzm Dr, Sakarya Üniversitesi Eğitim ve Araştırma Hastanesi, İç Hastalıklar BD, ahmedbgenc@gmail.com

² Doç Dr, Sakarya Üniversitesi Eğitim ve Araştırma Hastanesi, İç Hastalıklar BD, yaylaci@hotmail.com

KAYNAKÇA

1. Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. *JAMA*. 2020;323: 1239–1242.
2. Gavriatopoulou M, Korompoki E, Fotiou D, Ntanas-Stathopoulos I, Psaltopoulou T, Kastiris E, et al. Organ-specific manifestations of COVID-19 infection. *Clin Exp Med*. 2020;20: 493–506.
3. Signes-Costa J, Núñez-Gil IJ, Soriano JB, Arroyo-Espliguero R, Eid CM, Romero R, et al. Prevalence and 30-Day Mortality in Hospitalized Patients With Covid-19 and Prior Lung Diseases. *Arch Bronconeumol*. 2020. doi:10.1016/j.arbres.2020.11.012
4. Dreher M, Kersten A, Bickenbach J, Balfanz P, Hartmann B, Cornelissen C, et al. The Characteristics of 50 Hospitalized COVID-19 Patients With and Without ARDS. *Dtsch Arztebl Int*. 2020;117: 271–278.
5. Ferrando C, Mellado-Artigas R, Gea A, Arruti E, Aldcoa C, Bordell A, et al. Patient characteristics, clinical course and factors associated to ICU mortality in critically ill patients infected with SARS-CoV-2 in Spain: A prospective, cohort, multicentre study. *Rev Esp Anesthesiol Reanim*. 2020;67: 425–437.
6. Wang W, Gao R, Zheng Y, Jiang L. COVID-19 with spontaneous pneumothorax, pneumomediastinum and subcutaneous emphysema. *J Travel Med*. 2020;27. doi:10.1093/jtm/taaa062
7. Yamaya T, Baba T, Hagiwara E, Ikeda S, Niwa T, Kitayama T, et al. Pneumothorax in a COVID-19 Pneumonia Patient without Underlying Risk Factors. *Intern Med*. 2020;59: 2921–2925.
8. Martinelli AW, Ingle T, Newman J, Nadeem I, Jackson K, Lane ND, et al. COVID-19 and pneumothorax: a multicentre retrospective case series. *Eur Respir J*. 2020;56. doi:10.1183/13993003.02697-2020
9. Akel T, Qaqa F, Abuarqoub A, Shamoan F. Pulmonary embolism: A complication of COVID 19 infection. *Thromb Res*. 2020;193: 79–82.
10. Fauvel C, Weizman O, Trimaille A, Mika D, Pommer T, Pace N, et al. Pulmonary embolism in COVID-19 patients: a French multicentre cohort study. *Eur Heart J*. 2020;41: 3058–3068.
11. Gupta A, Madhavan MV, Sehgal K, Nair N, Mahajan S, Sehrawat TS, et al. Extrapulmonary manifestations of COVID-19. *Nat Med*. 2020;26: 1017–1032.
12. Chen L-W, Teng C-K, Tsai Y-S, Wang J-N, Tu Y-F, Shen C-F, et al. Influenza-associated neurological complications during 2014-2017 in Taiwan. *Brain Dev*. 2018;40: 799–806.
13. Beghi E, Feigin V, Caso V, Santalucia P, Logroscino G. COVID-19 Infection and Neurological Complications: Present Findings and Future Predictions. *Neuroepidemiology*. 2020;54: 364–369.
14. Garg RK. Spectrum of Neurological Manifestations in Covid-19: A Review. *Neurol India*. 2020;68: 560–572.
15. Niazkar HR, Zibae B, Nasimi A, Bahri N. The neurological manifestations of COVID-19: a review article. *Neurol Sci*. 2020;41: 1667–1671.
16. Gefen AM, Palumbo N, Nathan SK, Singer PS, Castellanos-Reyes LJ, Sethna CB. Pediatric COVID-19-associated rhabdomyolysis: a case report. *Pediatr Nephrol*. 2020;35: 1517–1520.
17. Anwar H, Al Lawati A. Adolescent COVID-19-Associated Fatal Rhabdomyolysis. *J Prim Care Community Health*. 2020;11: 2150132720985641.
18. Ellul MA, Benjamin L, Singh B, Lant S, Michael BD, Easton A, et al. Neurological associations of COVID-19. *Lancet Neurol*. 2020;19: 767–783.
19. Sohal S, Mansur M. COVID-19 Presenting with Seizures. *IDCases*. 2020;20: e00782.
20. Moriguchi T, Harii N, Goto J, Harada D, Sugawara H, Takamino J, et al. A first case of meningitis/encephalitis associated with SARS-Coronavirus-2. *Int J Infect Dis*. 2020;94: 55–58.
21. Oguz-Akarsu E, Ozpar R, Mirzayev H, Acet-Ozturk NA, Hakyemez B, Ediger D, et al. Guillain-Barré Syndrome in a Patient With Minimal Symptoms of COVID-19 Infection. *Muscle Nerve*. 2020;62: E54–E57.
22. Poyiadji N, Shahin G, Noujaim D, Stone M, Patel S, Griffith B. COVID-19-associated Acute Hemorrhagic Necrotizing Encephalopathy: Imaging Features. *Radiology*. 2020;296: E119–E120.
23. Iltaf S Sr, Fatima M, Salman S Sr, Salam J-U, Abbas S. Frequency of Neurological Presentations of Coronavirus Disease in Patients Presenting to a Tertiary Care Hospital During the 2019 Coronavirus Disease Pandemic. *Cureus*. 2020;12: e9846.
24. Meng X, Deng Y, Dai Z, Meng Z. COVID-19 and anosmia: A review based on up-to-date knowledge. *Am J Otolaryngol*. 2020;41: 102581.
25. Tian W, Jiang W, Yao J, Nicholson CJ, Li RH, Sigurslid HH, et al. Predictors of mortality in hospitalized COVID-19 patients: A systematic review and meta-analysis. *J Med Virol*. 2020;92: 1875–1883.
26. Wadhwa RK, Shen C, Gondi S, Chen S, Kazi DS, Yeh RW. Cardiovascular Deaths During the COVID-19 Pandemic in the United States. *J Am Coll Cardiol*. 2021;77: 159–169.
27. Çınar T, Hayiroğlu Mİ, Çiçek V, Uzun M, Orhan AL. COVID-19 and acute myocarditis: current literature review and diagnostic challenges. *Rev Assoc Med Bras*. 2020;66Suppl 2: 48–54.

28. Kumar R, Kumar J, Daly C, Edroos SA. Acute pericarditis as a primary presentation of COVID-19. *BMJ Case Rep.* 2020;13. doi:10.1136/bcr-2020-237617
29. Halushka MK, Vander Heide RS. Myocarditis is rare in COVID-19 autopsies: cardiovascular findings across 277 postmortem examinations. *Cardiovasc Pathol.* 2021;50: 107300.
30. Bhatt AS, Jering KS, Vaduganathan M, Claggett BL, Cunningham JW, Rosenthal N, et al. Clinical Outcomes in Patients With Heart Failure Hospitalized With COVID-19. *JACC Heart Fail.* 2021;9: 65–73.
31. Braiteh N, Rehman WU, Alom M, Skovira V, Breiteh N, Rehman I, et al. Decrease in acute coronary syndrome presentations during the COVID-19 pandemic in upstate New York. *Am Heart J.* 2020;226: 147–151.
32. Yalamanchi R, Dasari BC, Narra L, Oomman A, Kumar P, Nayak R, et al. Cardiac Intensive Care Unit Admissions during COVID-19 Pandemic-A Single Center Experience. *Indian J Crit Care Med.* 2020;24: 1103–1105.
33. Mina A, van Besien K, Plataniias LC. Hematological manifestations of COVID-19. *Leuk Lymphoma.* 2020;61: 2790–2798.
34. Terpos E, Ntanasis-Stathopoulos I, Elalamy I, Kastiritis E, Sergentanis TN, Politou M, et al. Hematological findings and complications of COVID-19. *Am J Hematol.* 2020;95: 834–847.
35. Li Q, Cao Y, Chen L, Wu D, Yu J, Wang H, et al. Hematological features of persons with COVID-19. *Leukemia.* 2020;34: 2163–2172.
36. Iba T, Connors JM, Levy JH. The coagulopathy, endotheliopathy, and vasculitis of COVID-19. *Inflamm Res.* 2020;69: 1181–1189.
37. Tal S, Spectre G, Kornowski R, Perl L. Venous Thromboembolism Complicated with COVID-19: What Do We Know So Far? *Acta Haematol.* 2020;143: 417–424.
38. Ribes A, Vardon-Bounes F, Mémier V, Poette M, Au-Duong J, Garcia C, et al. Thromboembolic events and Covid-19. *Adv Biol Regul.* 2020;77: 100735.
39. Hansrivijit P, Qian C, Boonpheng B, Thongprayoon C, Vallabhajosyula S, Cheungpasitporn W, et al. Incidence of acute kidney injury and its association with mortality in patients with COVID-19: a meta-analysis. *J Investig Med.* 2020;68: 1261–1270.
40. Chaudhri I, Moffitt R, Taub E, Annadi RR, Hoai M, Bolotova O, et al. Association of Proteinuria and Hematuria with Acute Kidney Injury and Mortality in Hospitalized Patients with COVID-19. *Kidney Blood Press Res.* 2020;45: 1018–1032.
41. Kunutsor SK, Laukkanen JA. Renal complications in COVID-19: a systematic review and meta-analysis. *Ann Med.* 2020;52: 345–353.
42. Chan L, Chaudhary K, Saha A, Chauhan K, Vaid A, Zhao S, et al. AKI in Hospitalized Patients with COVID-19. *J Am Soc Nephrol.* 2021;32: 151–160.
43. Jin J-M, Bai P, He W, Wu F, Liu X-F, Han D-M, et al. Gender Differences in Patients With COVID-19: Focus on Severity and Mortality. *Front Public Health.* 2020;8: 152.
44. Grasselli G, Greco M, Zanella A, Albano G, Antonelli M, Bellani G, et al. Risk Factors Associated With Mortality Among Patients With COVID-19 in Intensive Care Units in Lombardy, Italy. *JAMA Intern Med.* 2020;180: 1345–1355.
45. Li X, Xu S, Yu M, Wang K, Tao Y, Zhou Y, et al. Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan. *J Allergy Clin Immunol.* 2020;146: 110–118.
46. Patanavanich R, Glantz SA. Smoking Is Associated With COVID-19 Progression: A Meta-analysis. *Nicotine Tob Res.* 2020;22: 1653–1656.
47. Jiménez-Ruiz CA, López-Padilla D, Alonso-Arroyo A, Aleixandre-Benavent R, Solano-Reina S, de Granda-Orive JJ. COVID-19 and Smoking: A Systematic Review and Meta-Analysis of the Evidence. *Arch Bronconeumol.* 2021;57 Suppl 1: 21–34.
48. Reddy RK, Charles WN, Sklavounos A, Dutt A, Seed PT, Khajuria A. The effect of smoking on COVID-19 severity: A systematic review and meta-analysis. *J Med Virol.* 2021;93: 1045–1056.
49. Hussain A, Mahawar K, Xia Z, Yang W, El-Hasani S. Obesity and mortality of COVID-19. *Meta-analysis.* *Obes Res Clin Pract.* 2020;14: 295–300.
50. Malik P, Patel U, Patel K, Martin M, Shah C, Mehta D, et al. Obesity a predictor of outcomes of COVID-19 hospitalized patients-A systematic review and meta-analysis. *J Med Virol.* 2021;93: 1188–1193.
51. Jafarzadeh A, Jafarzadeh S, Nozari P, Mokhtari P, Nemati M. Lymphopenia an important immunological abnormality in patients with COVID-19: Possible mechanisms. *Scand J Immunol.* 2021;93: e12967.
52. Li X, Xu Z, Wang T, Xu X, Li H, Sun Q, et al. Clinical laboratory characteristics of severe patients with coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis. *Clin Epidemiol Glob Health.* 2021;9: 184–190.
53. Huang I, Pranata R. Lymphopenia in severe coronavirus disease-2019 (COVID-19): systematic review and meta-analysis. *J Intensive Care Med.* 2020;8: 36.
54. Lin J, Yan H, Chen H, He C, Lin C, He H, et al. COVID-19 and coagulation dysfunction in adults: A systematic review and meta-analysis. *J Med Virol.* 2021;93: 934–944.
55. Lippi G, Plebani M, Henry BM. Thrombocytopenia is associated with severe coronavirus disease

- 2019 (COVID-19) infections: A meta-analysis. *Clin Chim Acta*. 2020;506: 145–148.
56. Zong X, Gu Y, Yu H, Li Z, Wang Y. Thrombocytopenia Is Associated with COVID-19 Severity and Outcome: An Updated Meta-Analysis of 5637 Patients with Multiple Outcomes. *Lab Med*. 2021;52: 10–15.
57. Asakura H, Ogawa H. COVID-19-associated coagulopathy and disseminated intravascular coagulation. *Int J Hematol*. 2021;113: 45–57.
58. Zhang L, Yan X, Fan Q, Liu H, Liu X, Liu Z, et al. D-dimer levels on admission to predict in-hospital mortality in patients with Covid-19. *J Thromb Haemost*. 2020;18: 1324–1329.
59. Smilowitz NR, Kunichoff D, Garshick M, Shah B, Pilling M, Hochman JS, et al. C-reactive protein and clinical outcomes in patients with COVID-19. *Eur Heart J*. 2021. doi:10.1093/eurheartj/ehaa1103
60. Hu R, Han C, Pei S, Yin M, Chen X. Procalcitonin levels in COVID-19 patients. *Int J Antimicrob Agents*. 2020;56: 106051.
61. Vanhomwegen C, Veliziotis I, Malinverni S, Konopnicki D, Dechamps P, Claus M, et al. Procalcitonin accurately predicts mortality but not bacterial infection in COVID-19 patients admitted to intensive care unit. *Ir J Med Sci*. 2021. doi:10.1007/s11845-020-02485-z
62. Han Y, Zhang H, Mu S, Wei W, Jin C, Tong C, et al. Lactate dehydrogenase, an independent risk factor of severe COVID-19 patients: a retrospective and observational study. *Aging*. 2020;12: 11245–11258.
63. Henry BM, Aggarwal G, Wong J, Benoit S, Vikse J, Plebani M, et al. Lactate dehydrogenase levels predict coronavirus disease 2019 (COVID-19) severity and mortality: A pooled analysis. *Am J Emerg Med*. 2020;38: 1722–1726.
64. Zaninotto M, Mion MM, Padoan A, Babuin L, Plebani M. Cardiac troponin I in SARS-CoV-2-patients: The additional prognostic value of serial monitoring. *Clin Chim Acta*. 2020;511: 75–80.
65. Majure DT, Gruberg L, Saba SG, Kvasnovsky C, Hirsch JS, Jauhar R, et al. Usefulness of Elevated Troponin to Predict Death in Patients With COVID-19 and Myocardial Injury. *Am J Cardiol*. 2021;138: 100–106.
66. Violi F, Cangemi R, Romiti GF, Ceccarelli G, Oliva A, Alessandri F, et al. Is Albumin Predictor of Mortality in COVID-19? *Antioxid Redox Signal*. 2020. doi:10.1089/ars.2020.8142
67. Huang W, Li C, Wang Z, Wang H, Zhou N, Jiang J, et al. Decreased serum albumin level indicates poor prognosis of COVID-19 patients: hepatic injury analysis from 2,623 hospitalized cases. *Sci China Life Sci*. 2020;63: 1678–1687.
68. Paliogiannis P, Mangoni AA, Cangemi M, Fois AG, Carru C, Zinellu A. Serum albumin concentrations are associated with disease severity and outcomes in coronavirus 19 disease (COVID-19): a systematic review and meta-analysis. *Clin Exp Med*. 2021. doi:10.1007/s10238-021-00686-z.
69. Ulhaq ZS, Soraya GV. Interleukin-6 as a potential biomarker of COVID-19 progression. *Med Mal Infect*. 2020;50: 382–383.
70. Coomes EA, Haghbayan H. Interleukin-6 in Covid-19: A systematic review and meta-analysis. *Rev Med Virol*. 2020;30: 1–9.
71. Ponti G, Maccaferri M, Ruini C, Tomasi A, Ozben T. Biomarkers associated with COVID-19 disease progression. *Crit Rev Clin Lab Sci*. 2020;57: 389–399.
72. Abers MS, Delmonte OM, Ricotta EE, Fintzi J, Fink DL, de Jesus AAA, et al. An immune-based biomarker signature is associated with mortality in COVID-19 patients. *JCI Insight*. 2021;6. doi:10.1172/jci.insight.144455.
73. Genç AB, Yaylaci S, Dheir H, Genç AC, İşsever K, Çekiç D, et al. The predictive and diagnostic accuracy of long Pentraxin-3 in COVID-19 Pneumonia. *Turk J Med Sci*. 2020. doi:10.3906/sag-2011-32
74. Varım C, Demirci T, Cengiz H, Hacıbekiroğlu İ, Tuncer FB, Çokluk E, et al. Relationship between serum osteopontin levels and the severity of COVID-19 infection. *Wien Klin Wochenschr*. 2020. doi:10.1007/s00508-020-01789-5
75. Chen Y, Wang J, Liu C, Su L, Zhang D, Fan J, et al. IP-10 and MCP-1 as biomarkers associated with disease severity of COVID-19. *Mol Med*. 2020;26: 97.